Key Events This Week
Mar 09: Intraday low hit amid price pressure (Rs.608.40)
Mar 09: Technical momentum shifts to sideways trend
Mar 10: Downgrade to Sell rating announced
Mar 11: Technical momentum shifts to mildly bearish despite intraday gain
March 9: Intraday Price Pressure Amid Broader Market Weakness
Anthem Biosciences Ltd opened the week under pressure, falling sharply to an intraday low of Rs.608.40, a 7.96% drop from the previous close. The stock closed at Rs.660.00, down 0.16% on the day, underperforming amid a broadly negative market environment where the Sensex declined 1.91%. This decline was driven by sector underperformance and technical weakness, with the stock trading below all key moving averages and enduring a seven-day losing streak. The intraday low highlighted significant selling pressure, reflecting investor caution in the Pharmaceuticals & Biotechnology sector.
March 9: Technical Momentum Shifts to Sideways Amid Market Volatility
On the same day, technical indicators signalled a shift from mildly bullish to sideways momentum. The stock traded between Rs.653.10 and Rs.672.00, consolidating after recent volatility. Key momentum indicators such as MACD and RSI showed neutral readings, while weekly Bollinger Bands turned bearish, suggesting increased near-term volatility. The sideways trend indicated a pause in upward momentum, with the stock’s Mojo Score at 50.0 and a Hold rating, reflecting a balanced but cautious outlook amid sector headwinds.
Crushing the market! This Small Cap from Aerospace & Defense just earned its spot in our Top 1% with impressive gains. Don't let this opportunity slip through your hands.
- - Recent Top 1% qualifier
- - Impressive market performance
- - Sector leader
March 10: Downgrade to Sell Amid Technical and Financial Weakness
MarketsMOJO downgraded Anthem Biosciences Ltd from Hold to Sell on 9 March 2026, citing deteriorating technical indicators and disappointing quarterly financial results. Despite strong management efficiency with a return on equity of 19.93% and zero debt, the company reported a 24.2% decline in profit before tax and a 14.1% drop in profit after tax for Q3 FY 2025-26. Net sales also fell to ₹423.15 crores, the lowest in recent quarters, signalling operational challenges. The stock’s valuation at a price-to-book ratio of 13 was deemed expensive relative to earnings growth, raising concerns about risk-reward balance amid slowing momentum.
March 11: Technical Momentum Turns Mildly Bearish Despite Intraday Gains
On 11 March, Anthem Biosciences closed at Rs.672.00, up 1.82% intraday, but technical momentum shifted from sideways to mildly bearish. The weekly MACD remained mildly bullish, yet volume indicators such as On-Balance Volume were bearish, suggesting weak institutional support. Bollinger Bands turned bullish, indicating expanding volatility, but Dow Theory and other momentum indicators signalled caution. The stock’s Mojo Score declined to 40.0 with a Sell rating, reflecting increased technical and fundamental concerns. Despite outperforming the Sensex’s 2.53% fall with a 2.13% weekly decline, the mixed signals underscored a complex outlook.
Considering Anthem Biosciences Ltd? Wait! SwitchER has found potentially better options in and beyond. Compare this mid-cap with top-rated alternatives now!
- - Better options discovered
- - + beyond scope
- - Top-rated alternatives ready
Daily Price Performance vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-03-09 | Rs.660.00 | -0.16% | 34,557.39 | -1.91% |
| 2026-03-10 | Rs.670.00 | +1.52% | 35,005.20 | +1.30% |
| 2026-03-11 | Rs.648.45 | -3.22% | 34,529.78 | -1.36% |
| 2026-03-12 | Rs.640.25 | -1.26% | 34,300.49 | -0.66% |
| 2026-03-13 | Rs.639.90 | -0.05% | 33,516.43 | -2.29% |
Key Takeaways
1. Price Pressure and Volatility: The stock faced significant intraday pressure early in the week, hitting a low of Rs.608.40 on 9 March, reflecting broader market weakness and sector-specific challenges.
2. Technical Momentum Shifts: Anthem Biosciences transitioned from a mildly bullish to sideways, then mildly bearish technical trend, signalling uncertainty and consolidation amid volatile market conditions.
3. Downgrade to Sell: The downgrade by MarketsMOJO on 9 March was driven by disappointing quarterly results, expensive valuation multiples, and weakening technical indicators, signalling increased downside risk.
4. Relative Outperformance: Despite the weekly 3.20% decline, Anthem Biosciences outperformed the Sensex’s 4.87% fall, demonstrating relative resilience amid a challenging market environment.
Conclusion
The week ending 13 March 2026 was challenging for Anthem Biosciences Ltd, marked by significant price volatility, a technical momentum shift to a more cautious stance, and a downgrade to a Sell rating amid disappointing financial results. While the stock outperformed the broader Sensex decline, the combination of operational headwinds, expensive valuation, and mixed technical signals suggests a cautious outlook. Investors should closely monitor upcoming quarterly updates and technical developments to assess whether the stock can stabilise or face further pressure in the near term.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
